Related Experiment Videos
Itraconazole for deep mycoses: preliminary experience in Mexico
Reviews of Infectious Diseases
|January 1, 1987
Summary
Itraconazole effectively treated deep mycoses in eight patients, including coccidioidomycosis, chromomycosis, and sporotrichosis. Most patients achieved cure or marked improvement with oral itraconazole therapy, with no reported adverse reactions.
Area of Science:
- Mycology
- Dermatology
- Infectious Diseases
Background:
- Deep mycoses are serious fungal infections requiring effective treatment.
- Itraconazole is an oral antifungal agent used for various fungal infections.
Purpose of the Study:
- To evaluate the efficacy and safety of oral itraconazole in treating deep mycoses.
- To assess treatment outcomes for patients with coccidioidomycosis, chromomycosis, and sporotrichosis.
Main Methods:
- Retrospective evaluation of eight patients treated with oral itraconazole.
- Dosage ranged from 100-200 mg daily, with treatment duration based on clinical and mycological response.
- Regular clinical and mycological assessments were performed throughout treatment.
Main Results:
- Cures were achieved in coccidioidomycosis (1 patient), lymphangitic sporotrichosis (1 patient), sporotrichosis (2 patients), and chromomycosis (1 patient).
- Marked improvement was observed in one patient with sporotrichosis and one with chromomycosis.
- Two patients required higher doses (200 mg/day) for successful treatment. No adverse reactions were reported.
Conclusions:
- Oral itraconazole is an effective and well-tolerated treatment for deep mycoses, including coccidioidomycosis, chromomycosis, and sporotrichosis.
- Treatment duration and dosage may need to be individualized based on the specific mycosis and patient response.
- Further studies are warranted to confirm these findings in larger patient cohorts.